Drug Profile
TNX 801
Alternative Names: Smallpox and monkeypox vaccines - Tonix Pharmaceuticals/University of Alberta; TNX-801Latest Information Update: 31 Oct 2023
Price :
$50
*
At a glance
- Originator Leder Laboratories; University of Alberta
- Developer Tonix Pharmaceuticals Holding Corp
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Monkeypox; Smallpox
Most Recent Events
- 19 Oct 2023 Tonix Pharmaceuticals plans a phase I/II trial for smallpox and monkeypox (Prevention) (SC)
- 19 Oct 2023 Pharmacodynamics data from a preclinical trial in smallpox and monkeypox released by Tonix Pharmaceuticals
- 21 Aug 2023 Tonix plans submission of IND to the US FDA to develop TNX 8011 vaccine for the protection against Monkeypox and Smallpox (Prevention)